GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » EBIT

Vaxxinity (Vaxxinity) EBIT : $-56.24 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity EBIT?

Vaxxinity's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-11.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-56.24 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vaxxinity's annualized ROC % for the quarter that ended in Dec. 2023 was -345.20%. Vaxxinity's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -403.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vaxxinity's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1,426.30%.


Vaxxinity EBIT Historical Data

The historical data trend for Vaxxinity's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity EBIT Chart

Vaxxinity Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
-13.73 -38.78 -136.34 -74.71 -56.24

Vaxxinity Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.21 -18.23 -13.83 -12.97 -11.21

Competitive Comparison of Vaxxinity's EBIT

For the Biotechnology subindustry, Vaxxinity's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxxinity's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxxinity's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vaxxinity's EV-to-EBIT falls into.



Vaxxinity EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxxinity  (OTCPK:VAXX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vaxxinity's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-46.6 * ( 1 - 0% )/( (12.454 + 14.545)/ 2 )
=-46.6/13.4995
=-345.20 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Vaxxinity's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-44.84/( ( (11.123 + max(-16.8, 0)) + (11.081 + max(-13.278, 0)) )/ 2 )
=-44.84/( ( 11.123 + 11.081 )/ 2 )
=-44.84/11.102
=-403.89 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.43) - (20.23 + 0 + 0)
=-16.8

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.421) - (14.141 + 0 + 1.558)
=-13.278

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vaxxinity's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-56.239/-3.943
=1,426.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxxinity EBIT Related Terms

Thank you for viewing the detailed overview of Vaxxinity's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxxinity (Vaxxinity) Business Description

Traded in Other Exchanges
N/A
Address
505 Odyssey Way, Merritt Island, FL, USA, 32953
Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.
Executives
Sumita Ray officer: Chief Legal Officer, Secretary C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp 10 percent owner P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano director 209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese director, officer: Executive Chairman C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu director, 10 percent owner, officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc 10 percent owner 25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss 10 percent owner 126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig director 625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui director C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292